Replimune
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
500 Unicorn Park Dr Fl 3, Woburn, Massac...Phone Number
(781) 222-9600Website
www.replimune.comRevenue
-Stock Symbol
REPLIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
2
2
2
About Replimune
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response. Replimune is a biotech company focused on revolutionizing cancer treatment with a new class of oncolytic immunotherapies intended to activate a powerful and durable full-body anti-tumor response.Explore more
Replimune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Replimune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Replimune is spiking on competitors!
Product Launch: Get notified when Replimune launches new products
Website visits: Recent activity has been detected on your website
Click to see if Replimune had a recent Job posting/layoffs
Check if Replimune has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Replimune
Funding: Get notified immidiatlly once Replimune has new funding data
Earning: See what the market has to say on Replimune recently announced quarterly report
Replimune, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Replimune
Find 3 more new buyers
Compare Similar Companies to Replimune
Compare insights from companies similar to Replimune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Replimune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Replimune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Replimune.
Replimune financials insights
Gather financial insights about Replimune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$30M
2017
Series B
$55M
2018
Stock Offering
$111M
2019
Stock Offering
$80M
2020
Stock Offering
$100M
2026
Stock/Share Issuance
$150M
Replimune Tech Stack
A closer look at the technologies used by Replimune
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Replimune News & Media
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their OptionsBronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or...REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
Investors allege Replimune Group, Inc. told the market its RP1 resubmission was a complete response to the FDA's prior deficiency letter, while the agency's evidentiary standards for an "adequate and well-controlled" trial allegedly were never satisfied. NEW YORK, Sept. 9, 2026...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Replimune
Sign Up For FreeTo access detailed company insights
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response. Replimune is a biotech company focused on revolutionizing cancer treatment with a new clas... Read More
